Initiative for Medicines, Access & Knowledge (@IMAKglobal) header
Initiative for Medicines, Access & Knowledge (@IMAKglobal) profile picture

We are a team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.

Joined May 2015
Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)Photo by Initiative for Medicines, Access & Knowledge (@IMAKglobal)
Pomalyst, Darzalex, and Trelegy Ellipta account for $9.9 billion in annual Medicare spending, ranking among the highest-cost drugs in the program. Why are these drugs so expensive, and why has generic or biosimilar competition failed to materialize? The answer lies in what we call the ‘Monopoly Extension Menu’—a set of overlapping schemes that pharmaceutical companies deploy to exploit the U.S. patent system in order to maintain market exclusivity. reports.i-mak.org/monopoly-e…
6
1
5
1,193
Initiative for Medicines, Access & Knowledge retweeted
The most common question I am asked is, “How do I break into the antitrust field?” I usually give a hodgepodge of advice. Today, to keep supporting the antimonopoly movement, I’m releasing a free document that covers everything you need to know. papers.ssrn.com/sol3/papers.…
16
117
20
746
67,427
Initiative for Medicines, Access & Knowledge retweeted
For nearly five years @AdamMossoff & a network of pharma industry & patent system gatekeepers have tried to discredit my org, @IMAKglobal, and me personally. They will keep failing. We will continue exposing how patent abuse makes medicines unaffordable for millions of Americans.
1
3
1
2
242
Initiative for Medicines, Access & Knowledge retweeted
Patents are supposed to reward innovation, not prevent competition. In the first episode of our three-part Red Tape series, @RSI's Wayne T. Brough explores how the patent system can hinder competition and keep prescription drug prices unnecessarily high. Watch the video here: youtu.be/8DhoonhYa3o?si=S3Kd…
1
1
2
1,207
Initiative for Medicines, Access & Knowledge retweeted
No patent thickets to see here, right @USPTO @Council4IP?
1
3
7
397
Initiative for Medicines, Access & Knowledge retweeted
What exactly is a patent thicket? 💊 @RSI's Wayne T. Brough breaks down how overlapping patents can create barriers to competition, delaying access to more affordable medicines. Watch our latest explainer!
4
3
4
7
1,927
Last week, @realtahiramin, @reshmagar, and @cmorten2 sat down to discuss pharmaceutical monopolies and what it will take to end the drug pricing crisis. Thank you to everyone who came out, and to @nyulaw for hosting!
4
5
227
Thank you to everyone who joined us for @EconomicSecProj's conversation with @realtahiramin and @gabyaboulafia on how corporate power is driving the healthcare affordability crisis!
3
6
213
Initiative for Medicines, Access & Knowledge retweeted
Looking forward to two conversations next week in NYC on the occasion of my book, Pharma Monopoly. On Monday, I’ll be speaking with @reshmagar and @cmorten2 at NYU. Then on Tuesday I’ll be in conversation with @gabyaboulafia at Bibliotheque. Both free and open to the public.
1
3
1
4
392
Initiative for Medicines, Access & Knowledge retweeted
Please join @gabyaboulafia and me for conversation on corporate power, healthcare costs, and the fight for affordability. Thank you @EconomicSecProj for organising! Bibliotheque, 54 Mercer Street, NYC Oct 20, 5-7pm Free and open to the public with RSVP: tahir-amin.com/events/monopo…
3
3
242
NYC! Join us next week for two free events on pharma monopolies, corporate power, and building a pharmaceutical system that works for the public good!
Looking forward to two conversations next week in NYC on the occasion of my book, Pharma Monopoly. On Monday, I’ll be speaking with @reshmagar and @cmorten2 at NYU. Then on Tuesday I’ll be in conversation with @gabyaboulafia at Bibliotheque. Both free and open to the public.
1
1
2
141
NYC! Join us for a deep dive into @realtahiramin's new book, Pharma Monopoly, and how corporate power is driving the healthcare affordability crisis. Bibliotheque (54 Mercer Street) Tuesday, October 20 5-7PM Featuring: @realtahiramin and @gabyaboulafia of @EconomicSecProj RSVP: tahir-amin.com/events/monopo…
2
4
162
America is witnessing a surge in psychedelic bioprospecting. According to Psychedelic Alpha, there are 59 clinical trials using psychedelic agents right now, including ten in Phase 3. Americans are likely to see the first FDA-approved versions of psilocybin- and LSD-based treatments within a year. Treatments based on toad venom (5-MeO-DMT) and the West African iboga root (ibogaine) could be up for FDA approval within the coming years. The medicalization and commercialization of naturally occurring and other psychedelic substances is underway—and drug companies are poised to own everything that comes out of it. i-mak.org/2026/10/08/monopol…
1
3
122
Important victory! Indonesia’s Constitutional Court recently struck down a provision in a law that allowed patent evergreening. “Patent rights should not be understood merely as an economic privilege, but also as rights carrying a dimension of social responsibility,” the court wrote. “Protection of inventors is necessary to sustain innovation, but at the same time, the benefits and impacts of innovation are intertwined with the interests of society.” This is a win for patients and competition. Thank you to our colleagues around the world who continue to fight back against corporate patent abuse and expansionist patent policies. statnews.com/pharmalot/2026/…
2
140
Initiative for Medicines, Access & Knowledge retweeted
I’ll be discussing my co-authored book Pharma Monopoly on Oct 19 at NYU with @cmorten2 and @reshmagar. The event is free and open to all with RSVP. Please join us! eventbrite.com/e/pharma-mono…
3
3
429
NYC! Our CEO @realtahiramin will be discussing his new book, Pharma Monopoly, with NYU Associate Professor of Law @cmorten2 and Yale Professor of Medicine @reshmagar on October 19. Monday, October 19 6-8PM NYU Law Vanderbilt Hall Greenberg Lounge 40 Washington Square South, NYC RSVP here: eventbrite.com/e/pharma-mono…
1
4
295
“The patent system has shifted from being about invention to being about innovation…We live in a world where these big pharmaceutical companies are not doing the inventing. They’re doing these tweaks, these modifications.” - @realtahiramin on the Mostly Economics podcast
4
2
2
2
998
What would it look like to have a real counterweight to a pharmaceutical industry that increasingly caters only to those who can pay the most? @realtahiramin and @DeanBaker13 discuss on the @ceprdc Mostly Economics podcast.
3
4
424
Initiative for Medicines, Access & Knowledge retweeted
One of the easiest ways to root out patent abuse is to scrutinize every instance a corporation claims they are "innovating.” It’s code for lifecycle management, i.e. squeezing maximum revenue from existing products while minimizing investment.
2
1
8
603